Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabi W van Pelt

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Oncotarget|March 9, 2019
Tumor stroma as contributing factor in the lymph node metastases process?Wilma E Mesker, Gabi W van Pelt, Rob A E M Tollenaar
Histopathology|September 13, 2017
In reply to Hynes et al.: 'Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stages II/III colon cancer in a large population-based study'Gabi W van Pelt, Anouck Huijbers, Rob A E M Tollenaar, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 20, 2013
Clinical application of circulating tumor cells in breast cancerLeonie H A Broersen, Gabi W van Pelt, Rob A E M Tollenaar, et al.
Oncotarget|May 2, 2019
Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal contentTessa P Sandberg, Jan Oosting, Gabi W van Pelt, et al.
Oncotarget|August 25, 2018
Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal contentTessa P Sandberg, Jan Oosting, Gabi W van Pelt, et al.
British Journal of Cancer|May 15, 2018
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancerStéphanie M Zunder, Gabi W van Pelt, Hans J Gelderblom, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 16, 2016
High-Throughput and High-Sensitivity Mass Spectrometry-Based N-Glycomics of Mammalian CellsStephanie Holst, Gabi W van Pelt, Wilma E Mesker, et al.
Journal of Surgical Oncology|February 16, 2018
The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trialAnouck Huijbers, Gabi W van Pelt, Rachel S Kerr, et al.
Cancer Research|May 20, 2016
c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 PathwayYihao Li, Ke Jin, Gabi W van Pelt, et al.
JMIR Formative Research|March 19, 2021
e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED StudyMarloes A Smit, Gabi W van Pelt, Elisabeth Mc Dequeker, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Oncotarget|March 9, 2019
Tumor stroma as contributing factor in the lymph node metastases process?Wilma E Mesker, Gabi W van Pelt, Rob A E M Tollenaar
Histopathology|September 13, 2017
In reply to Hynes et al.: 'Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stages II/III colon cancer in a large population-based study'Gabi W van Pelt, Anouck Huijbers, Rob A E M Tollenaar, et al.
Cellular Oncology (Dordrecht, Netherlands)|November 20, 2013
Clinical application of circulating tumor cells in breast cancerLeonie H A Broersen, Gabi W van Pelt, Rob A E M Tollenaar, et al.
Oncotarget|May 2, 2019
Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal contentTessa P Sandberg, Jan Oosting, Gabi W van Pelt, et al.
Oncotarget|August 25, 2018
Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal contentTessa P Sandberg, Jan Oosting, Gabi W van Pelt, et al.
British Journal of Cancer|May 15, 2018
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancerStéphanie M Zunder, Gabi W van Pelt, Hans J Gelderblom, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 16, 2016
High-Throughput and High-Sensitivity Mass Spectrometry-Based N-Glycomics of Mammalian CellsStephanie Holst, Gabi W van Pelt, Wilma E Mesker, et al.
Journal of Surgical Oncology|February 16, 2018
The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trialAnouck Huijbers, Gabi W van Pelt, Rachel S Kerr, et al.
Cancer Research|May 20, 2016
c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 PathwayYihao Li, Ke Jin, Gabi W van Pelt, et al.
JMIR Formative Research|March 19, 2021
e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED StudyMarloes A Smit, Gabi W van Pelt, Elisabeth Mc Dequeker, et al.
Pageof 4